摘要
层出不穷的试验研究和不断更新的指南使人们对冠心病防治的认识不断加深,但指南的实施和普及却不理想,大多数冠心病患者并未真正受益于降脂治疗。现就NCEP-ATP指南的更新和目前冠心病患者降脂治疗的现状、主要影响因素(患者的依从性、医务工作者的医疗质量、药物有效性以及效价比与经济条件)及可能的改善措施做一综述。
Recently, lots of experiments help us to know more about the prevention and care of coronary heart disease, with which treatment guidelines update times and become more clear. However,a major part of the population is not achieving the recommended LDL cholesterol target levels. This fact is more prominent among high-risk populations in which the majority of patients are un- treated or undertreated. The review will present the new changes of the treatment guidelines, elaborate on the current situation of lipid-lowering therapy of coronary heart disease and its key influencing factors： patient compliance, drug efficacy, cast - benefit, and physician quality of care. A programme aimed at improving control of hyperlipidemia should address all these four issues.
出处
《医学与哲学（B）》
2006年第4期56-59,共4页
Medicine & Philosophy(B)
关键词
冠心病
降脂治疗
NCEP—ATPⅢ
治疗指南
影响因素
coronary heart disease,lipid-lowering therapy,NCEP-ATPIII,treatment guidelines,lnfluencing factors
